Abstract
The aetiology of ovarian cancer is multifactorial with both endogenous and exogenous risk factors playing an important role. The exact pathogenesis of ovarian cancer is still not well understood, despite the number of hypotheses published. Due to an increase in the number of women using fertility drugs, much attention has been focused on the long-term health effects of such drugs. Although fertility drugs facilitate the ovulation process, it is however associated with a significant increase in hormone concentrations, placing exposed women at increased risk of gynaecological cancer. Many clinical and epidemiological studies have examined the association between fertility drugs and ovarian cancer risk. Results from these studies have been contradictory, as some studies have reported an increased risk of ovarian cancer while others reported no increased risk. Nevertheless, recent studies have shown that women who used fertility drugs and did not conceive had a higher risk of developing ovarian cancer, compared to women who used fertility drugs and conceived and delivered successfully. This review discusses the effect of fertility drugs on the risk of developing ovarian cancer, providing details on four possible scenarios associated with fertility treatment. In addition, the limitations of previous studies and their impact on our understanding of the association between fertility drugs and ovarian cancer have also been highlighted.
Keywords: Ovulation, nulliparity, inflammation, oxidative stress, ovarian cancer, fertility drugs.
Current Cancer Drug Targets
Title:Fertility Drugs and Ovarian Cancer
Volume: 18 Issue: 6
Author(s): Aus Tariq Ali*
Affiliation:
- Department of Pathology, Tygerberg Hospital and Stellenbosch Medical School, Cape-Town,south africa
Keywords: Ovulation, nulliparity, inflammation, oxidative stress, ovarian cancer, fertility drugs.
Abstract: The aetiology of ovarian cancer is multifactorial with both endogenous and exogenous risk factors playing an important role. The exact pathogenesis of ovarian cancer is still not well understood, despite the number of hypotheses published. Due to an increase in the number of women using fertility drugs, much attention has been focused on the long-term health effects of such drugs. Although fertility drugs facilitate the ovulation process, it is however associated with a significant increase in hormone concentrations, placing exposed women at increased risk of gynaecological cancer. Many clinical and epidemiological studies have examined the association between fertility drugs and ovarian cancer risk. Results from these studies have been contradictory, as some studies have reported an increased risk of ovarian cancer while others reported no increased risk. Nevertheless, recent studies have shown that women who used fertility drugs and did not conceive had a higher risk of developing ovarian cancer, compared to women who used fertility drugs and conceived and delivered successfully. This review discusses the effect of fertility drugs on the risk of developing ovarian cancer, providing details on four possible scenarios associated with fertility treatment. In addition, the limitations of previous studies and their impact on our understanding of the association between fertility drugs and ovarian cancer have also been highlighted.
Export Options
About this article
Cite this article as:
Ali Tariq Aus *, Fertility Drugs and Ovarian Cancer, Current Cancer Drug Targets 2018; 18 (6) . https://dx.doi.org/10.2174/1568009617666170620102049
DOI https://dx.doi.org/10.2174/1568009617666170620102049 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibition of Anti-Apoptotic Bcl-2 Family Proteins by Natural Polyphenols New Avenues for Cancer Chemoprevention and Chemotherapy
Current Pharmaceutical Design Current Status of Carbapenem Antibiotics
Current Topics in Medicinal Chemistry The PI3K Pathway at the Crossroads of Cancer and the Immune System: Strategies for Next Generation Immunotherapy Combinations
Current Cancer Drug Targets Postponing Motherhood: A Demographic and Contemporary Issue
Current Women`s Health Reviews Phosphodiesterase-5 Inhibitors: Future Perspectives
Current Pharmaceutical Design Protamine 2 Precursors and Processing
Protein & Peptide Letters Therapeutic Transfer of DNA Encoding Adenoviral E1A
Recent Patents on Anti-Cancer Drug Discovery Anesthetic and Adjunctive Drugs for Fast-Track Surgery
Current Drug Targets Relationship Between Body Mass Index and Reproduction
Current Women`s Health Reviews Peptides as Therapeutic Agents or Drug Leads for Autoimmune, Hormone Dependent and Cardiovascular Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Current State of the Art of New Tubulin Inhibitors in the Clinic
Current Clinical Pharmacology Clomiphene for the Treatment of Male Infertility: A Case Report of Mood Change and a Literature Overview
Current Drug Safety Uncommon Becoming Common: Case Series of Primary Fallopian Tube Cancers
Current Women`s Health Reviews The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer
Current Drug Targets The mRNA-HPV Test Utilization in the Follow Up of HPV Related Cervical Lesions
Current Pharmaceutical Design Type Specific Human Papilloma Virus Prevalence and Distribution in Women with Abnormal Cervical Cytology: A Single Centre Retrospective Observational Study in the Emirate of Abu Dhabi
New Emirates Medical Journal Literature Review: Use of Family History for Primary Paediatric Care as the Next Step Towards use of Genomics in Healthcare
Current Pediatric Reviews Editorial [Hot Topic: Surgical Treatment of Endometrial Cancer (Guest Editor: Maite Cusido Gimferrer)]
Current Women`s Health Reviews Cancer/Testis Antigens Trigger Epithelial-Mesenchymal Transition and Genesis of Cancer Stem-Like Cells
Current Pharmaceutical Design Standards and Novel Therapeutic Options in the Treatment of Patients with Soft Tissue Sarcoma
Reviews on Recent Clinical Trials